People can undergo accurate screening for pancreatic cancer during a routine health check, and patients with lung cancer and breast cancer can benefit from higher quality and better management through smart technology, precision medicine and innovative therapies.
Cancer detection, diagnosis and treatment are becoming increasingly accessible, accurate and effective, according to experts and industry insiders speaking at this year’s China International Import Expo.
Experts from Changhai Hospital announced in a livestreaming health education program that they have used artificial intelligence to develop a model for accurate and early screening of pancreatic cancer using standard CT scans.
Pancreatic cancer is known as the “King of Cancer” due to its low survival rate and difficulty in early detection.
Ti Gong
The AI-based solution for pancreatic cancer detection was published by the medical journal Nature Medicine.
Nearly 120,000 people are diagnosed with pancreatic cancer in China every year, and this number is increasing due to an aging population and changes in diet and lifestyle.
“Contrast-enhanced CT is usually used to detect pancreatic cancer, which regular CT cannot detect. However, patients who have no symptoms will not opt for an enhanced procedure,” said Dr. Cao Kai, a major project developer.
“So we created an intelligent model called PANDA, which uses AI technology to detect small differences between pixels and perform detailed analysis to identify pancreatic cancer. The accuracy is greater than 92 percent. The model is widely used in the clinical practice of our hospital. significantly improve the accuracy and timeliness of pancreatic cancer detection using a simple CT scan.”
“In addition to pancreatic cancer, the model can also be promoted for other cancer scans, such as liver cancer and esophageal cancer, greatly improving the efficiency of cancer detection and allowing patients to receive early diagnosis and early treatment,” he said.
Ti Gong
Zhou Lei, a breast cancer patient, shares her experiences with the Phesgo treatment.
In addition to pancreatic cancer, lung cancer, the most common cancer in China, is an important target for smart management.
Roche Pharmaceuticals collaborated with medical experts, patient organizations and the media to develop an intelligent system for the detection, diagnosis, treatment and rehabilitation of lung cancer for more effective and individualized patient care.
“Lung cancer services are tailored to patient needs, and innovative and intelligent methods such as AI make treatment more accurate. We are actively participating in the exploration and introduction of digital technologies such as AI to develop personalized treatment plans for each patient,” said Dr. Zhong Wenshao from Guangdong Province Lung Cancer Institute.
Breast cancer, the most common cancer in women, has been fully covered by targeted drugs as a result of accurate molecular testing and targeted medications.
Roche’s Phesgo, the world’s first anti-HER2 dual-target subcutaneous therapy for breast cancer, can now be delivered via a single subcutaneous injection lasting 5 to 8 minutes, significantly reducing dosing time from hours to minutes and giving patients a new, faster treatment is offered. and a less invasive treatment option.
Zhou Lei, a breast cancer patient undergoing Phesgo treatment, expressed her appreciation for the introduction of this convenient and highly effective therapy.
“We can let go of the long-standing stigma of being a cancer patient because we have more time to be ourselves and spend less time on treatment. It’s such a good feeling,” she said.
Thanks to advances in technology, doctors now have more tools to fight breast cancer, which is increasingly treated in outpatient clinics, communities and at home. As a result, patients benefit from a better treatment result and a higher quality of life.